TY - JOUR
T1 - Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents US Preventive Services Task Force Recommendation Statement
AU - US Preventive Services Task Force
AU - Mangione, Carol M.
AU - Barry, Michael J.
AU - Nicholson, Wanda K.
AU - Cabana, Michael
AU - Chelmow, David
AU - Coker, Tumaini Rucker
AU - Davidson, Karina W.
AU - Davis, Esa M.
AU - Donahue, Katrina E.
AU - Jaén, Carlos Roberto
AU - Kubik, Martha
AU - Li, Li
AU - Ogedegbe, Gbenga
AU - Pbert, Lori
AU - Ruiz, John M.
AU - Stevermer, James
AU - Tseng, Chien Wen
AU - Wong, John B.
N1 - Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/9/13
Y1 - 2022/9/13
N2 - IMPORTANCE The Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents. OBJECTIVE The US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation. POPULATION Children and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes. EVIDENCE ASSESSMENT The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined. RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents.
AB - IMPORTANCE The Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents. OBJECTIVE The US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation. POPULATION Children and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes. EVIDENCE ASSESSMENT The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined. RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents.
UR - http://www.scopus.com/inward/record.url?scp=85138445570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138445570&partnerID=8YFLogxK
U2 - 10.1001/jama.2022.14543
DO - 10.1001/jama.2022.14543
M3 - Article
C2 - 36098719
AN - SCOPUS:85138445570
SN - 0098-7484
VL - 328
SP - 963
EP - 967
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 10
ER -